Nymox Pharmaceutical Corp NYMXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYMXF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.28–0.28
- 52-Week Range
- $0.12–1.28
- Bid/Ask
- $0.25 / $0.31
- Market Cap
- $26.14 Mil
- Volume/Avg
- 401 / 17,066
Key Statistics
- Price/Earnings (Normalized)
- 0.67
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.nymox.com
Valuation
|
Metric
|
NYMXF
|
|---|---|
Price/Earnings (Normalized) | 0.67 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NYMXF
Financial Strength
|
Metric
|
NYMXF
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.25 |
Interest Coverage | −81.58 |
Quick Ratio
NYMXF
Profitability
|
Metric
|
NYMXF
|
|---|---|
Return on Assets (Normalized) | −372.15% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NYMXF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wyvckbxqt | Gfgx | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jbcmjxd | Sqzkcjm | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rdyfxfpbb | Spbcsxq | $105.3 Bil | |
MRNA
| Moderna Inc | Pdtpzpxgm | Ybkb | $46.7 Bil | |
ARGX
| argenx SE ADR | Ppktlsg | Wnyrn | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Pggbzcqvg | Fybp | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Smmlbpq | Wtfkg | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kjswdllb | Jsxjqq | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ynmzsccff | Nxrxsy | $12.6 Bil | |
INCY
| Incyte Corp | Zvjrkyw | Rhsrsv | $12.0 Bil |